These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 27876862)

  • 1. In Silico Exploration for Novel Type-I Inhibitors of Tie-2/TEK: The Performance of Different Selection Strategy in Selecting Virtual Screening Candidates.
    Pan P; Sun H; Liu H; Li D; Zhou W; Kong X; Li Y; Yu H; Hou T
    Sci Rep; 2016 Nov; 6():37628. PubMed ID: 27876862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and Preliminary SAR Analysis of Novel Type-I Inhibitors of TIE-2 via Structure-Based Virtual Screening and Biological Evaluation in in vitro Models.
    Pan P; Tian S; Sun H; Kong X; Zhou W; Li D; Li Y; Hou T
    J Chem Inf Model; 2015 Dec; 55(12):2693-704. PubMed ID: 26618892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable.
    Buttar D; Edge M; Emery SC; Fitzek M; Forder C; Griffen A; Hayter B; Hayward CF; Hopcroft PJ; Luke RW; Page K; Stawpert J; Wright A
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4723-6. PubMed ID: 18676144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virtual screening based on pharmacophore model followed by docking simulation studies in search of potential inhibitors for p38 map kinase.
    Shahlaei M; Doosti E
    Biomed Pharmacother; 2016 May; 80():352-372. PubMed ID: 27133076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivo.
    Luke RW; Ballard P; Buttar D; Campbell L; Curwen J; Emery SC; Griffen AM; Hassall L; Hayter BR; Jones CD; McCoull W; Mellor M; Swain ML; Tucker JA
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6670-4. PubMed ID: 19854647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Subtype Selective Janus Kinase (JAK) Inhibitors by Structure-Based Virtual Screening.
    Bajusz D; Ferenczy GG; Keserű GM
    J Chem Inf Model; 2016 Jan; 56(1):234-47. PubMed ID: 26682735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel anti-angiogenesis agents. Part 7: Multitarget inhibitors of VEGFR-2, TIE-2 and EphB4.
    Li C; Shan Y; Sun Y; Si R; Liang L; Pan X; Wang B; Zhang J
    Eur J Med Chem; 2017 Dec; 141():506-518. PubMed ID: 29102175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The discovery of aurora kinase inhibitor by multi-docking-based virtual screening.
    Kim JT; Jung SH; Kang SY; Ryu CK; Kang NS
    Int J Mol Sci; 2014 Nov; 15(11):20403-12. PubMed ID: 25383681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ensemble docking-based virtual screening yields novel spirocyclic JAK1 inhibitors.
    Bajusz D; Ferenczy GG; Keserű GM
    J Mol Graph Model; 2016 Nov; 70():275-283. PubMed ID: 27771575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors.
    Arcari JT; Beebe JS; Berliner MA; Bernardo V; Boehm M; Borzillo GV; Clark T; Cohen BD; Connell RD; Frost HN; Gordon DA; Hungerford WM; Kakar SM; Kanter A; Keene NF; Knauth EA; Lagreca SD; Lu Y; Martinez-Alsina L; Marx MA; Morris J; Patel NC; Savage D; Soderstrom CI; Thompson C; Tkalcevic G; Tom NJ; Vajdos FF; Valentine JJ; Vincent PW; Wessel MD; Chen JM
    Bioorg Med Chem Lett; 2013 May; 23(10):3059-63. PubMed ID: 23566514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 8-THP-DHI analogs as potent Type I dual TIE-2/VEGF-R2 receptor tyrosine kinase inhibitors.
    Hudkins RL; Zulli AL; Underiner TL; Angeles TS; Aimone LD; Meyer SL; Pauletti D; Chang H; Fedorov EV; Almo SC; Fedorov AA; Ruggeri BA
    Bioorg Med Chem Lett; 2010 Jun; 20(11):3356-60. PubMed ID: 20430619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase.
    Huang H; Ma J; Shi J; Meng L; Jiang H; Ding J; Liu H
    Bioorg Med Chem; 2010 Jul; 18(13):4615-24. PubMed ID: 20570525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of triarylimidazoles for Tie2: influence of conformation on potency.
    Johnson NW; Semones M; Adams JL; Hansbury M; Winkler J
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5514-7. PubMed ID: 17826092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases.
    Dandu R; Zulli AL; Bacon ER; Underiner T; Robinson C; Chang H; Miknyoczki S; Grobelny J; Ruggeri BA; Yang S; Albom MS; Angeles TS; Aimone LD; Hudkins RL
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1916-21. PubMed ID: 18308565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand efficiency based approach for efficient virtual screening of compound libraries.
    Ke YY; Coumar MS; Shiao HY; Wang WC; Chen CW; Song JS; Chen CH; Lin WH; Wu SH; Hsu JT; Chang CM; Hsieh HP
    Eur J Med Chem; 2014 Aug; 83():226-35. PubMed ID: 24960626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel potent human testis-specific and bromodomain-containing protein (BRDT) inhibitors using crystal structure-based virtual screening.
    Gao N; Ren J; Hou L; Zhou Y; Xin L; Wang J; Yu H; Xie Y; Wang H
    Int J Mol Med; 2016 Jul; 38(1):39-44. PubMed ID: 27220398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homology modeling and virtual screening for inhibitors of lipid kinase PI(4)K from Plasmodium.
    Ren JX; Gao NN; Cao XS; Hu QA; Xie Y
    Biomed Pharmacother; 2016 Oct; 83():798-808. PubMed ID: 27490781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An in silico high-throughput screen identifies potential selective inhibitors for the non-receptor tyrosine kinase Pyk2.
    Meirson T; Samson AO; Gil-Henn H
    Drug Des Devel Ther; 2017; 11():1535-1557. PubMed ID: 28572720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase.
    Cee VJ; Cheng AC; Romero K; Bellon S; Mohr C; Whittington DA; Bak A; Bready J; Caenepeel S; Coxon A; Deak HL; Fretland J; Gu Y; Hodous BL; Huang X; Kim JL; Lin J; Long AM; Nguyen H; Olivieri PR; Patel VF; Wang L; Zhou Y; Hughes P; Geuns-Meyer S
    Bioorg Med Chem Lett; 2009 Jan; 19(2):424-7. PubMed ID: 19062275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computer-aided discovery of aminopyridines as novel JAK2 inhibitors.
    Zhao C; Yang SH; Khadka DB; Jin Y; Lee KT; Cho WJ
    Bioorg Med Chem; 2015 Mar; 23(5):985-95. PubMed ID: 25650310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.